Arcturus Therapeutics (NASDAQ:ARCT) Coverage Initiated by Analysts at BTIG Research

Stock analysts at BTIG Research started coverage on shares of Arcturus Therapeutics (NASDAQ:ARCT) in a report released on Tuesday,Benzinga reports. The brokerage set a “buy” rating and a $41.00 price target on the biotechnology company’s stock. BTIG Research’s price objective suggests a potential upside of 149.54% from the stock’s current price.

ARCT has been the topic of several other research reports. Cantor Fitzgerald restated an “overweight” rating on shares of Arcturus Therapeutics in a research report on Monday, December 16th. HC Wainwright reissued a “buy” rating and set a $63.00 price target on shares of Arcturus Therapeutics in a report on Monday, January 13th. Seven research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Buy” and an average target price of $61.60.

Arcturus Therapeutics Price Performance

Shares of Arcturus Therapeutics stock opened at $16.43 on Tuesday. Arcturus Therapeutics has a 1 year low of $14.30 and a 1 year high of $45.00. The stock has a market cap of $445.04 million, a PE ratio of -7.40 and a beta of 2.63. The firm has a fifty day moving average price of $17.28 and a 200 day moving average price of $19.66.

Arcturus Therapeutics (NASDAQ:ARCT) last issued its quarterly earnings data on Thursday, November 7th. The biotechnology company reported ($0.26) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.70) by $0.44. The business had revenue of $41.67 million during the quarter, compared to analysts’ expectations of $49.16 million. Arcturus Therapeutics had a negative return on equity of 22.39% and a negative net margin of 36.39%. During the same quarter in the previous year, the firm posted ($0.61) EPS. As a group, equities analysts expect that Arcturus Therapeutics will post -2.31 EPS for the current year.

Institutional Investors Weigh In On Arcturus Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. nVerses Capital LLC purchased a new position in Arcturus Therapeutics during the third quarter valued at $42,000. China Universal Asset Management Co. Ltd. lifted its stake in Arcturus Therapeutics by 64.4% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 5,201 shares of the biotechnology company’s stock valued at $121,000 after buying an additional 2,038 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. acquired a new stake in Arcturus Therapeutics in the 2nd quarter worth about $142,000. SG Americas Securities LLC purchased a new stake in Arcturus Therapeutics during the 3rd quarter worth approximately $191,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in shares of Arcturus Therapeutics by 10.8% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 8,694 shares of the biotechnology company’s stock valued at $202,000 after acquiring an additional 846 shares during the last quarter. Hedge funds and other institutional investors own 94.54% of the company’s stock.

Arcturus Therapeutics Company Profile

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.